



Contacts:

Susan M. Kanaya
Senior Vice President, Finance and Chief
Financial Officer or

Markus J. Cappel, Ph.D.
Senior Vice President, Corporate &
Business Development
650-210-2900
investor@chemocentryx.com

For media inquiries:

BCC Partners
Karen L. Bergman
650-575-1509 or
Michelle Corral
415-794-8662

ChemoCentryx Names Regina E. Herzlinger to the Company's Board of Directors

Mountain View, CA, February 7, 2006 – ChemoCentryx, Inc., a clinical-stage, biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, today announced that the company has appointed Regina E. Herzlinger to the company's Board of Directors, effective immediately. Dr. Herzlinger is a Professor at the Harvard Business School and is well known for her expertise in healthcare industry business and accounting practices. In conjunction with Dr. Herzlinger's appointment, Peter Svenilson will step down from the ChemoCentryx Board. The total number of Board members remains the same.

"I am absolutely delighted to welcome Regi Herzlinger to the ChemoCentryx Board. We value her strategic insights into the business and management practices of the healthcare industry as we continue to advance our clinical-stage pipeline of chemokine-based medicines through development," said Thomas Schall, Ph.D., ChemoCentryx' President and CEO. "In particular, Regi's extensive experience serving on the Boards of public companies, combined with her knowledge of finance and corporate governance, will provide an excellent complement to our Board. In addition, I would like to thank Peter for his excellent work on our behalf."

"ChemoCentryx has created an impressive pipeline of small molecule medicines addressing inflammatory diseases. The company's expertise in the discovery and development of novel compounds targeting the chemokine system provides an exciting advantage and I am pleased to join their Board of Directors," said Dr. Herzlinger.

Regina E. Herzlinger is the Nancy R. McPherson Professor of Business Administration Chair at the Harvard Business School. She was the first woman to be tenured and chaired at Harvard Business School. Dr. Herzlinger is widely recognized for her innovative research in health care, including her early predictions of the unraveling of managed care and the rise of market and consumer-driven health care and health care focused factories, two terms that she coined. She has authored a number of books, including *Consumer-Driven Health Care: Implications for Providers, Payers and Policymakers*, *Market-Driven Health Care* and *Financial Accounting and Managerial Control of Nonprofit Organizations*. Her numerous articles have been featured in a variety of publications, including the *Journal of the American Medical Association*, *Modern Healthcare*, *Circulation*, *Healthcare Financial Management*, *Harvard Business Review*, *The Economist* and *The Wall Street Journal*. Dr. Herzlinger has served as a board member of many publicly-traded firms, most of which are in the health care sector. Dr. Herzlinger is currently on the board of WellCare Health Plans, Inc. Additionally, she has served on the Scientific Advisory Group to the U.S. Secretary of the Air Force. Dr. Herzlinger has been the recipient of several awards, including the Harvard Business School outstanding teacher award, the American College of Healthcare Executives' Hamilton Book of the Year award, the Healthcare Financial Management Association's Board of Directors award and Management Accounting's research prize. In addition, *Modern Healthcare* readers selected her as one of 2003's, 2004's and 2005's "100 Most Powerful People in Healthcare" and *Managed Healthcare* named her as one of health care's top ten thinkers. She received her Bachelor's Degree from MIT and her Doctorate from the Harvard Business School.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a complex network of chemokine molecules, or ligands, and receptors that regulates inflammation. ChemoCentryx has internally generated more than six clinical and preclinical stage programs, each targeting distinct chemokine receptors with different small molecule compounds. The company's compounds are designed to be highly potent with minimal side effects and orally available for improved patient compliance, as well as ease and efficiency of manufacture. ChemoCentryx' lead compound, Traficet-EN®, is currently in Phase II clinical development for the treatment of patients with moderate to severe Crohn's disease.

Any statements in this press release about ChemoCentryx' expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the timing, success and cost of preclinical research and clinical studies, (ii) the timing, acceptability and review

periods for regulatory filings, (iii) the availability of corporate partners, (iv) uncertainties relating to patent protection and intellectual property rights of third parties, (v) the impact of competitive products and technological changes, (vi) the availability of capital and the cost of capital, (vii) other vagaries in the biotechnology industry and (viii) other risks. ChemoCentryx undertakes no obligation to update or revise any forward-looking statements.

#